Delving into the Latest Updates on NYVAC-HIV-PT1 vaccine(National Institute of Allergy & Infectious Diseases) with Synapse

Overview

Basic Info

Drug Type

DNA vaccine, Prophylactic vaccine

Synonyms

NYVAC-HIV-PT1

Target

HIV gp140

Action

inhibitors

Mechanism

gp140 inhibitors(HIV gp140 inhibitors)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesUrogenital Diseases

Active Indication-

Inactive Indication

HIV Infections

Originator Organization

National Institute of Allergy & Infectious Diseases

Active Organization-

Inactive Organization

National Institute of Allergy & Infectious Diseases

Drug Highest PhaseDiscontinuedPhase 1

First Approval Date-

Regulation-

Login to view timeline

NOTE: This study has stopped enrolling new participants, and all study vaccinations for currently enrolled participants have been stopped.
Currently, there are no vaccines approved for the prevention of HIV infection, but there are many clinical trials taking place that are studying experimental HIV vaccines. The purpose of this study is to evaluate the safety and tolerability of three different HIV vaccine schedules in healthy, HIV-uninfected adults.

Start Date01 Apr 2013

Sponsor / Collaborator

National Institute of Allergy & Infectious Diseases

NCT01799954

/ CompletedPhase 1IIT

A Phase 1 Double Blind Placebo-controlled Clinical Trial to Evaluate the Safety and to Compare the Priming Ability of NYVAC Alone Versus NYVAC + AIDSVAX® B/E, and DNA Alone Versus DNA + AIDSVAX® B/E When Followed by NYVAC + AIDSVAX® B/E Boosts in Healthy, HIV-1-uninfected Adult Participants

This study will evaluate the safety of and the body's immune response to experimental HIV vaccine regimens using different vaccine priming combination, and boosting with the vaccines NYVAC and AIDSVAX® B/E.

Start Date01 Aug 2012

Sponsor / Collaborator

HIV Vaccine Trials Network

NCT01927835

/ WithdrawnPhase 1IIT

A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Homologous and Heterologous Prime-Boost Regimens Comprising DNA-HIV-PT123, NYVAC-HIV-PT1 and NYVAC-HIV-PT4, and AIDSVAX B/E in Healthy, HIV-Uninfected US and South African Adults

The purpose of this study is to evaluate the safety and immune response to two different HIV vaccine regimens in healthy, HIV-uninfected people in the United States and South Africa.

Start Date-

Sponsor / Collaborator

National Institute of Allergy & Infectious Diseases

[+4]

100 Clinical Results associated with NYVAC-HIV-PT1 vaccine(National Institute of Allergy & Infectious Diseases)

Login to view more data

100 Translational Medicine associated with NYVAC-HIV-PT1 vaccine(National Institute of Allergy & Infectious Diseases)

Login to view more data

100 Patents (Medical) associated with NYVAC-HIV-PT1 vaccine(National Institute of Allergy & Infectious Diseases)

Login to view more data

100 Deals associated with NYVAC-HIV-PT1 vaccine(National Institute of Allergy & Infectious Diseases)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HIV Infections	Phase 1	United States	National Institute of Allergy & Infectious Diseases	01 Apr 2013
HIV Infections	Phase 1	Switzerland	National Institute of Allergy & Infectious Diseases	01 Apr 2013